trial
-
Telormedix’s TMX-101 exhibits high safety in phase I/II for non-muscle invasive bladder cancer
Telormedix announced that it has successfully completed the safety portion of a Phase I/II trial for TMX-101.
trial | 04 May 2012
-
Aslan Pharmaceuticals selects PharmaNet/i3 as partner for oncology development
Aslan Pharmaceuticals has selected PharmaNet/i3 as a partner supporting the development of their oncology portfolio in Asia.
trial | 02 May 2012
-
INCIVEK is well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens
Phase 2 study of INCIVEK combination regimen shows 74 percent of people co-infected with hepatitis C, HIV had undetectable hepatitis C virus 12 weeks after treatment ended.
trial | 30 April 2012
-
US FDA clears investigational new drug application, phase 2B trial for Immuron’s NASH/Fatty liver therapeutic
Immuron announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission to commence a Phase 2b clinical trial of its bovine colostrum-derived therapeutic (IMM-124E) for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Fatty Liver.
trial | 06 March 2012
-
Molecular Profiles invests in new facility to increase manufacturing capabilities for clinical trials
Molecular Profiles, a leading specialist contract research and manufacturing organization, announces the commencement of construction of a new manufacturing facility. This £9 million investment will allow Molecular Profiles to expand its current manufacturing capabilities while strengthening its existing expertise in the drug development field.
trial | 19 January 2012
-
US government HIV/AIDS clinical trial sites to accelerate completion of Phase III TB drug trial
The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ (NIAID) AIDS Clinical Trial Group (ACTG) to conduct and help complete a Phase III clinical trial testing potentially faster-acting tuberculosis (TB) treatments.
trial | 09 January 2012
-
ViroMed receives approval for Phase II trial in the US for diabetic peripheral neuropathy
ViroMed announced that VM202-DPN, the company's proprietary DNA medicine for treatment of diabetic peripheral neuropathy, has received approval from the US FDA for a Phase II clinical trial.
trial | 04 January 2012
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
trial | 18 November 2011
-
New data presented on phase 3 trial Of ELIQUIS (apixaban) in the prevention of venous thromboembolism in patients with acute medical illness
Bristol-Myers Squibb and Pfizer announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30.
trial | 15 November 2011
-
Phase 3 trial of Regorafenib in metastatic colorectal cancer meets primary endpoint of improving overall survival
Bayer HealthCare announced positive results from its Phase 3 trial evaluating its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.
trial | 31 October 2011
